

Our vision

Increase the survival rate of terminal Cancer patients by utilizing breakthrough oncolytic viruses based products to cure or transform terminal diseases into chronic and manageable ones.

The Company

ViruCure Therapeutics, established in 2016, develops a novel Oncolytic Newcastle Disease Virus (NDV) platform (called NADAV) for the treatment of a wide range of cancer types. This proprietary NDV technology was developed in the Hebrew University of Jerusalem.

NADAV Oncolytic platform technology

NDV in nature is an avian virus that has several levels of virulence towards chickens. Our platform is comprised from several proprietary attenuated lentogenic strains of the genetically stable oncolytic NDV, which kills cancer cells and do not cause severe illness in birds and humans. Based on both pre-clinical and clinical studies, NDV strains presented the following cancer therapy advantages:

- 1. Specific targeting of tumor cells**, due to various Mechanisms of Actions (MoAs).
- 2. Amplifying effect:** Continuous replication beyond initial dose and further tumor cells & metastases elimination.
- 3. Multiple effect:** Direct tumor cells killing, followed by additional immune system triggering against the cancerous cells that regularly manage to escape the immune system recognition.
- 4. Safe:** As NADAV's natural host are avian species it does not cause adverse effects in humans resulting in high efficiency & safety.

Outstanding Proof-of-Concept Clinical Trial Results

A phase I/II clinical trial on 12 terminal recurrent Glioblastoma Multiforme (GBM) patients (prognosis of life expectancy was approximately 4-6 weeks) using attenuated NDV (NDV-HUJ) strain, patients treated intravenously. Resulted in:

4/12 responded with - observable tumor shrinkage and a significant longevity survival rate, exceeding their medical prognosis. One patient exhibited complete remission. No significant side effects were recorded during the study and 6 of the patients lived over eight months.

Primary Target Indications

NADAV is a robust platform, demonstrating its significant oncolytic potential effect on various cancer types with specific promising results in recurrent Glioblastoma Multiforme (GBM). ViruCure's initial target is Glioblastoma Multiforme (GBM), a rare, lethal brain tumor with high unmet therapeutic need. The GBM market is expected to grow to \$3.3B by 2024 at a CAGR of 17.4%. VCT-GBM-101 is eligible for both Orphan Drug and breakthrough designations.

Key Team Members

Yoram Drucker, CEO and Co-Founder: >20 years of Bio-executive experience. Co-Founder, developed public traded companies such as Pluristem (PSTI) and BrainStorm (BCLI).

Dr. Shay Tayeb, CTO and Co-Founder: Vast research experience focused on NDV and its MoA models; lecturer in various bio- fields including virology and gene therapy.

Dr. Stephen Cherkez, Senior Vice President-intellectual property: Certified patent attorney. Former Head of Teva Chemical Research, Founder, President of ChemAgis. Previously VP-BD of Agis and VP-IP at Perrigo Int.

Zacki Turkeltaub, Senior member of GCA, Industry expert & Business Development Advisor: Extensive early-and late-stage life science innovations senior executive experience with track record of billiondollar JV and licensing transactions. Former senior member of the global industry.

Dr. Christian Policard, Senior member of GCA, Board member, PhD in Biochemistry, leadership across the spectrum of scientific & BD in the biomedical and biopharmaceutical arena. EVP of Diagnostics and Agro-Veterinary, Chairman of Sanofi USA, Leader of New Activities (Corporate Venture) at Sanofi-Synthelabo and member of its World Wide Executive Committee. EVP Business Development of Institut Pasteur and Chairman of Collectis.

David Goren, Senior member of GCA, Board member, Former head of Global Strategic Planning and BD of Pfizer Inc., President of AstraZeneca Israel establishing its commercial and R&D operations.

Dr. Asher Holzer, Board Member: Physicist; serial entrepreneur with >30 years of healthcare senior leadership experience. Vast experience in turning companies public.

Business Strategy

1. Two granted patents and further IP applications on the way.
2. Accomplish value-adding milestones via product manufacturing through CMO and GBM clinical trials.
3. As a designated breakthrough cancer therapy for orphan indications (such as GBM), regulators are giving accelerated process and market protection. Moreover revenues can begin while Phase 3 trial due to compassion treatments in designated countries.
4. Initial sales will be focused on US & EU markets, due to strategic potential collaborations with leading pharmaceutical companies.
5. ViruCure plans strategic collaborations with reputable research institutes and global pharmaceutical companies for additional applications.

Accelerated Regulatory Pathways

Orphan drug designation – provides reduced R&D costs, fast track to market, a platform for strategic JV, extended product exclusivity.

Breakthrough drug designation – provides extended data exclusivity (>11years), possible accelerated regulatory approval.

Use of Proceeds

1. GBM Clinical trials.
2. Establish current NADAV bio-production process (with a CMO).
3. Development of 2nd Gen. NADAV (new indications, higher efficiency).
4. Bio-Marker identification.

Why to invest in ViruCure Therapeutics

- Breakthrough unique technology, human clinical outstanding Proof of Concept, in-vivo indications for other types of cancers such as: Colorectal cancer, Advanced Melanoma, Lung and Head & Neck cancer.
- Paradigm changing technology in the field of cancer therapy and treatment regimen.
- Extensive scientific knowledge and in-depth understanding of NADAV MoAs.
- Lower investment risks due to accelerated regulatory opportunities (Orphan designation, Breakthrough designation).
- Clear strategic/financial roadmap, upon having clinical data of GBM (planned at end of Y3) aiming towards public markets horizon.
- A strong team of Global Key Opinion Leaders within the Company field of expertise, global advisory board and reputable international corporate board members.

Scientific Advisory Board

Prof. Amos Panet: Professor of Virology at the Hebrew University. Former CSO & research director at BTG; Co-Founder of ViruCure.

Prof. Zichriya Zakay-Rones: Professor of Virology at the Hebrew University. Expert in NDV vaccines and oncolytic activity; Co-Founder of ViruCure.

Prof. Nir Peled: Committee co-chair of the Lung Cancer studies International Association. Head of the Oncology department in Soroka medical center. Firm engagement with the global lung cancer care segment.

Dr. Corinne Szilagyi: Life and health sciences professional at Pfizer. Vast expertise in drugs and biologics development, cell-based therapeutics. Senior partner at BDC consulting firm specialized in BD & corporation strategy.

Disclaimer

The matters discussed in this document are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the company could differ significantly from those statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of the company or any entity.

Contact:

Yoram Drucker

Tel: +972.54.471.1171

yoram.drucker@virucure.com

The logo for Virucure Therapeutics features the word "Virucure" in a bold, black, sans-serif font. A purple triangle is positioned to the left of the letter "V". Below "Virucure", the word "Therapeutics" is written in a smaller, black, sans-serif font.